Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration

International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG)

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in breast and other cancers. However, clinical utility of the immunohistochemical (IHC) assay for Ki67 immunohistochemistry has been hampered by unacceptable between-laboratory analytical variability. The International Ki67 Working Group has conducted a series of studies aiming to decrease this variability and improve the evaluation of Ki67. This study tries to assess whether acceptable performance can be achieved on prestained core-cut biopsies using a standardized scoring method. Sections from 30 primary ER+ breast cancer core biopsies were centrally stained for Ki67 and circulated among 22 laboratories in 11 countries. Each laboratory scored Ki67 using three methods: (1) global (4 fields of 100 cells each); (2) weighted global (same as global but weighted by estimated percentages of total area); and (3) hot-spot (single field of 500 cells). The intraclass correlation coefficient (ICC), a measure of interlaboratory agreement, for the unweighted global method (0.87; 95% credible interval (CI): 0.81–0.93) met the prespecified success criterion for scoring reproducibility, whereas that for the weighted global (0.87; 95% CI: 0.7999–0.93) and hot-spot methods (0.84; 95% CI: 0.77– 0.92) marginally failed to do so. The unweighted global assessment of Ki67 IHC analysis on core biopsies met the prespecified criterion of success for scoring reproducibility. A few cases still showed large scoring discrepancies. Establishment of external quality assessment schemes is likely to improve the agreement between laboratories further. Additional evaluations are needed to assess staining variability and clinical validity in appropriate cohorts of samples.

Original languageEnglish (US)
Article number16014
Journalnpj Breast Cancer
Volume2
Issue number1
DOIs
StatePublished - Dec 14 2016

Fingerprint

Biopsy
Breast Neoplasms
Research Design
Biomarkers
Immunohistochemistry
Staining and Labeling

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG) (2016). Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration. npj Breast Cancer, 2(1), [16014]. https://doi.org/10.1038/npjbcancer.2016.14

Analytical validation of a standardized scoring protocol for Ki67 : Phase 3 of an international multicenter collaboration. / International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG).

In: npj Breast Cancer, Vol. 2, No. 1, 16014, 14.12.2016.

Research output: Contribution to journalArticle

International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG) 2016, 'Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration', npj Breast Cancer, vol. 2, no. 1, 16014. https://doi.org/10.1038/npjbcancer.2016.14
International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG). Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration. npj Breast Cancer. 2016 Dec 14;2(1). 16014. https://doi.org/10.1038/npjbcancer.2016.14
International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG). / Analytical validation of a standardized scoring protocol for Ki67 : Phase 3 of an international multicenter collaboration. In: npj Breast Cancer. 2016 ; Vol. 2, No. 1.
@article{4f2ae83f4ebe49399ef18f0aebf44ac1,
title = "Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration",
abstract = "Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in breast and other cancers. However, clinical utility of the immunohistochemical (IHC) assay for Ki67 immunohistochemistry has been hampered by unacceptable between-laboratory analytical variability. The International Ki67 Working Group has conducted a series of studies aiming to decrease this variability and improve the evaluation of Ki67. This study tries to assess whether acceptable performance can be achieved on prestained core-cut biopsies using a standardized scoring method. Sections from 30 primary ER+ breast cancer core biopsies were centrally stained for Ki67 and circulated among 22 laboratories in 11 countries. Each laboratory scored Ki67 using three methods: (1) global (4 fields of 100 cells each); (2) weighted global (same as global but weighted by estimated percentages of total area); and (3) hot-spot (single field of 500 cells). The intraclass correlation coefficient (ICC), a measure of interlaboratory agreement, for the unweighted global method (0.87; 95{\%} credible interval (CI): 0.81–0.93) met the prespecified success criterion for scoring reproducibility, whereas that for the weighted global (0.87; 95{\%} CI: 0.7999–0.93) and hot-spot methods (0.84; 95{\%} CI: 0.77– 0.92) marginally failed to do so. The unweighted global assessment of Ki67 IHC analysis on core biopsies met the prespecified criterion of success for scoring reproducibility. A few cases still showed large scoring discrepancies. Establishment of external quality assessment schemes is likely to improve the agreement between laboratories further. Additional evaluations are needed to assess staining variability and clinical validity in appropriate cohorts of samples.",
author = "{International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG)} and Leung, {Samuel C.Y.} and Nielsen, {Torsten O.} and Lila Zabaglo and Indu Arun and Badve, {Sunil S.} and Bane, {Anita L.} and Bartlett, {John M.S.} and Signe Borgquist and Chang, {Martin C.} and Andrew Dodson and Enos, {Rebecca A.} and Fineberg, {Susan A.} and Focke, {Cornelia M.} and Dongxia Gao and Gown, {Allen M.} and Dorthe Grabau and Carolina Gutierrez and Hugh, {Judith C.} and Zuzana Kos and L{\ae}nkholm, {Anne Vibeke} and Lin, {Ming Gang} and Mastropasqua, {Mauro G.} and Takuya Moriya and Sharon Nofech-Mozes and Osborne, {C. Kent} and Penault-Llorca, {Fr{\'e}d{\'e}rique M.} and Tammy Piper and Takashi Sakatani and Roberto Salgado and Jane Starczynski and Giuseppe Viale and Hayes, {Daniel F.} and McShane, {Lisa M.} and Mitch Dowsett",
year = "2016",
month = "12",
day = "14",
doi = "10.1038/npjbcancer.2016.14",
language = "English (US)",
volume = "2",
journal = "npj Breast Cancer",
issn = "2374-4677",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Analytical validation of a standardized scoring protocol for Ki67

T2 - Phase 3 of an international multicenter collaboration

AU - International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG)

AU - Leung, Samuel C.Y.

AU - Nielsen, Torsten O.

AU - Zabaglo, Lila

AU - Arun, Indu

AU - Badve, Sunil S.

AU - Bane, Anita L.

AU - Bartlett, John M.S.

AU - Borgquist, Signe

AU - Chang, Martin C.

AU - Dodson, Andrew

AU - Enos, Rebecca A.

AU - Fineberg, Susan A.

AU - Focke, Cornelia M.

AU - Gao, Dongxia

AU - Gown, Allen M.

AU - Grabau, Dorthe

AU - Gutierrez, Carolina

AU - Hugh, Judith C.

AU - Kos, Zuzana

AU - Lænkholm, Anne Vibeke

AU - Lin, Ming Gang

AU - Mastropasqua, Mauro G.

AU - Moriya, Takuya

AU - Nofech-Mozes, Sharon

AU - Osborne, C. Kent

AU - Penault-Llorca, Frédérique M.

AU - Piper, Tammy

AU - Sakatani, Takashi

AU - Salgado, Roberto

AU - Starczynski, Jane

AU - Viale, Giuseppe

AU - Hayes, Daniel F.

AU - McShane, Lisa M.

AU - Dowsett, Mitch

PY - 2016/12/14

Y1 - 2016/12/14

N2 - Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in breast and other cancers. However, clinical utility of the immunohistochemical (IHC) assay for Ki67 immunohistochemistry has been hampered by unacceptable between-laboratory analytical variability. The International Ki67 Working Group has conducted a series of studies aiming to decrease this variability and improve the evaluation of Ki67. This study tries to assess whether acceptable performance can be achieved on prestained core-cut biopsies using a standardized scoring method. Sections from 30 primary ER+ breast cancer core biopsies were centrally stained for Ki67 and circulated among 22 laboratories in 11 countries. Each laboratory scored Ki67 using three methods: (1) global (4 fields of 100 cells each); (2) weighted global (same as global but weighted by estimated percentages of total area); and (3) hot-spot (single field of 500 cells). The intraclass correlation coefficient (ICC), a measure of interlaboratory agreement, for the unweighted global method (0.87; 95% credible interval (CI): 0.81–0.93) met the prespecified success criterion for scoring reproducibility, whereas that for the weighted global (0.87; 95% CI: 0.7999–0.93) and hot-spot methods (0.84; 95% CI: 0.77– 0.92) marginally failed to do so. The unweighted global assessment of Ki67 IHC analysis on core biopsies met the prespecified criterion of success for scoring reproducibility. A few cases still showed large scoring discrepancies. Establishment of external quality assessment schemes is likely to improve the agreement between laboratories further. Additional evaluations are needed to assess staining variability and clinical validity in appropriate cohorts of samples.

AB - Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in breast and other cancers. However, clinical utility of the immunohistochemical (IHC) assay for Ki67 immunohistochemistry has been hampered by unacceptable between-laboratory analytical variability. The International Ki67 Working Group has conducted a series of studies aiming to decrease this variability and improve the evaluation of Ki67. This study tries to assess whether acceptable performance can be achieved on prestained core-cut biopsies using a standardized scoring method. Sections from 30 primary ER+ breast cancer core biopsies were centrally stained for Ki67 and circulated among 22 laboratories in 11 countries. Each laboratory scored Ki67 using three methods: (1) global (4 fields of 100 cells each); (2) weighted global (same as global but weighted by estimated percentages of total area); and (3) hot-spot (single field of 500 cells). The intraclass correlation coefficient (ICC), a measure of interlaboratory agreement, for the unweighted global method (0.87; 95% credible interval (CI): 0.81–0.93) met the prespecified success criterion for scoring reproducibility, whereas that for the weighted global (0.87; 95% CI: 0.7999–0.93) and hot-spot methods (0.84; 95% CI: 0.77– 0.92) marginally failed to do so. The unweighted global assessment of Ki67 IHC analysis on core biopsies met the prespecified criterion of success for scoring reproducibility. A few cases still showed large scoring discrepancies. Establishment of external quality assessment schemes is likely to improve the agreement between laboratories further. Additional evaluations are needed to assess staining variability and clinical validity in appropriate cohorts of samples.

UR - http://www.scopus.com/inward/record.url?scp=85012134592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012134592&partnerID=8YFLogxK

U2 - 10.1038/npjbcancer.2016.14

DO - 10.1038/npjbcancer.2016.14

M3 - Article

AN - SCOPUS:85012134592

VL - 2

JO - npj Breast Cancer

JF - npj Breast Cancer

SN - 2374-4677

IS - 1

M1 - 16014

ER -